Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

• If you are looking at FMC and wondering whether the recent share price puts it in bargain territory or value trap territory, this article is for you.
• The stock last closed at US$14.33, with returns of 0.3% over 7 days, a 10.5% decline over 30 days, and longer term returns of 0.1% decline year to date, 62.7% decline over 1 year, 86.2% decline over 3 years, and 84.8% decline over 5 years.
• These sharp moves have kept FMC in focus as investors reassess what the current price really reflects about the business and its risks. That context makes it especially important to look beyond the headline chart and understand how different valuation tools line up on the stock today.
• On Simply Wall St’s 6 point valuation checklist, FMC scores a 5. Next we will walk through what that means across multiple valuation approaches, before finishing with a broader way to think about the company’s value story.

Find out why FMC’s -62.7% return over the last year is lagging behind its peers.

Approach 1: FMC Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today’s dollars to arrive at an implied value per share.

For FMC, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in $. The latest twelve month free cash flow is a loss of about $161.4 million. Analysts provide explicit forecasts out to 2028, with free cash flow for that year projected at $177.45 million. Beyond that, Simply Wall St extends the projections out to 2035, with annual free cash flows through that period ranging from tens to a few hundred million dollars each year.

After discounting these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $20.15 per share. Compared with the recent share price of $14.33, this implies the stock is 28.9% undervalued based purely on this cash flow framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests FMC is undervalued by 28.9%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

FMC Discounted Cash Flow as at Mar 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for FMC.

Approach 2: FMC Price vs Sales

For companies where earnings are weak or volatile, the P/S ratio is often more useful than P/E because it compares the share price to revenue rather than profit, which can swing around more from year to year.

What investors are really weighing with any valuation multiple is how the market is pricing a company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher “normal” multiple, while lower growth or higher risk usually points to a lower one.

FMC currently trades on a P/S ratio of 0.52x. That sits below the Chemicals industry average P/S of 1.10x and also below the peer average of 1.78x. On the face of it, the stock is being valued at a lower level of sales than many of its sector peers.

Simply Wall St’s Fair Ratio for FMC is 1.71x. This is a proprietary estimate of what the P/S could be, given factors such as the company’s earnings profile, industry, profit margin, market cap and risk characteristics. Because it blends these elements, the Fair Ratio can give a more tailored anchor than a simple comparison with industry or peer averages.

Comparing the Fair Ratio of 1.71x with the current P/S of 0.52x suggests FMC is trading below that implied fair range.

Result: UNDERVALUED

NYSE:FMC P/S Ratio as at Mar 2026

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your FMC Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by linking your view of FMC’s future revenue, earnings and margins to a forecast and fair value estimate. You can then compare that fair value with today’s price to help you decide if the stock looks appealing or stretched. Each Narrative lives on the Community page, updates automatically as new news or earnings arrive, and captures different viewpoints. For example, one FMC Narrative anchors around a Fair Value of US$13.00 with slower growth and lower margins, and another uses a Fair Value of about US$44.05 with higher assumed growth and profitability. This allows you to see exactly how different assumptions create very different conclusions about the same company.

For FMC however we’ll make it really easy for you with previews of two leading FMC Narratives:

Start by asking yourself which of these feels closer to how you see the business over the next few years, then use that to frame how you read any single valuation model.

🐂 FMC Bull Case

Fair value in this bullish Narrative: about US$18.12 per share.

At the last close of US$14.33, the price sits roughly 20.9% below that fair value anchor.

Annual revenue growth assumption: about 5.47%.

• Assumes solid revenue contribution from FMC’s newer proprietary actives and higher margin Biologicals and Plant Health products, with growth focused on regions such as Brazil and EMEA.
• Includes potential benefits from cost restructuring, lower manufacturing costs and shifts in go to market models, with the goal of improving EBITDA margins and future free cash flow.
• Acknowledges risks from regulation, generics, pricing pressure and leverage, and assumes FMC manages these well enough for earnings and margins to improve over time.

🐻 FMC Bear Case

Fair value in this bearish Narrative: US$13.00 per share.

At the last close of US$14.33, the price sits about 10.2% above that fair value anchor.

Annual revenue growth assumption: about 2.77%.

• Focuses on pressure from tighter regulation, moves toward organic and regenerative farming, and rising generic competition that could weigh on demand and margins for FMC’s conventional products.
• Assumes more modest revenue growth and lower profit margins, with concerns that R&D spending and the product mix may not fully keep pace with shifts in crop protection and ag tech.
• Uses the lowest analyst price target of US$37.00 as a reference point and frames the current share price as close to fairly valued under cautious assumptions about earnings, multiples and discount rates.

If you want to go beyond these snapshots and see how your own assumptions stack up against other investors’ models, Curious how numbers become stories that shape markets? Explore Community Narratives.

Do you think there’s more to the story for FMC? Head over to our Community to see what others are saying!

NYSE:FMC 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include FMC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com